Patents by Inventor Salah Mecheri

Salah Mecheri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Plasmodium with histamine releasing factor (HRF) deficiency for use as a vaccine
    Patent number: 11642404
    Abstract: A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate.
    Type: Grant
    Filed: January 18, 2021
    Date of Patent: May 9, 2023
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Salah Mecheri, Robert Menard, Claudia Demarta-Gatsi
  • PLASMODIUM WITH HISTAMINE RELEASING FACTOR (HRF) DEFICIENCY FOR USE AS A VACCINE
    Publication number: 20210393760
    Abstract: A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate.
    Type: Application
    Filed: January 18, 2021
    Publication date: December 23, 2021
    Inventors: Salah MECHERI, Robert MENARD, Claudia DEMARTA-GATSI
  • Plasmodium with histamine releasing factor (HRF) deficiency for use as a vaccine
    Patent number: 10898564
    Abstract: A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: January 26, 2021
    Inventors: Salah Mecheri, Robert Menard, Claudia Demarta-Gatsi
  • PLASMODIUM WITH HISTAMINE RELEASING FACTOR (HRF) DEFICIENCY FOR USE AS A VACCINE
    Publication number: 20190282680
    Abstract: A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate.
    Type: Application
    Filed: July 18, 2017
    Publication date: September 19, 2019
    Inventors: Salah MECHERI, Robert MENARD, Claudia DEMARTA-GATSI
  • Protein product, process for making it and pharmaceutical composition containing said protein
    Patent number: 4559230
    Abstract: New product consisting of glycoprotein having a molecular weight of about 14,000 and an isoelectric point of about 4.6, its absorption spectrum having an absorption of .epsilon.=0.12 units of optical density (O.D.) at 280 nm for an aqueous solution of 1 mg (dry weight) per ml of water. This product has immunoregulating properties and is useful in allergic therapeutic composition.
    Type: Grant
    Filed: March 23, 1983
    Date of Patent: December 17, 1985
    Assignee: Institut Pasteur
    Inventors: Bernard David, Gabriel Peltre, Salah Mecheri